What changed in Moderna, Inc.'s latest annual report
In the year ended 31 Dec 2025, Moderna, Inc.'s revenue fell 39.9% to USD 1.94bn, from USD 3.24bn; cash and cash equivalents rose 34.7% to USD 2.60bn, from USD 1.93bn; shareholders' equity fell 20.6% to USD 8.65bn, from USD 10.90bn.
Year ended 31 Dec 2025. Source: 10-K filed 20 Feb 2026, read it on SEC EDGAR.
USD 3.24bn to USD 1.94bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 3.24bn | 1.94bn | Down 39.9% |
| Net income | -3.56bn | -2.82bn | Not comparable |
| Total assets | 14.14bn | 12.34bn | Down 12.8% |
| Total liabilities | 3.24bn | 3.69bn | Up 13.8% |
| Long-term debt | 0 | 590.00m | Not comparable |
| Cash and cash equivalents | 1.93bn | 2.60bn | Up 34.7% |
| Shareholders' equity | 10.90bn | 8.65bn | Down 20.6% |
Questions people ask
Did Moderna, Inc.'s revenue grow last year?
Revenue fell 39.9%, from USD 3.24bn to USD 1.94bn in the year ended 31 Dec 2025.
Is Moderna, Inc. profitable?
Not in its latest year: it reported a net loss of USD 2.82bn in the year ended 31 Dec 2025. The year before: a net loss of USD 3.56bn.
How much cash and debt does Moderna, Inc. have?
At its latest year end (31 Dec 2025), Moderna, Inc. reported cash and cash equivalents of USD 2.60bn and long-term debt of USD 590.00m.
Where do these numbers come from?
From Moderna, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Moderna, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%
- Repligen CorpCash and cash equivalents down 25.3%